Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers

We previously reported the safety and efficacy of low dose BaP [Bezafibrate (Bez) and Medroxyprogesterone acetate (MPA)] in 20 acute myeloid leukaemia (AML) patients for whom chemotherapy was not an option. This study provided evidence that BaP had anti-AML activity and improved haemopoiesis; absenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Jim, Pratt, Guy, Jacob, Abe, Clark, Fiona, Blundred, Rachel, Fox, Sonia, Bishop, Rebecca, Wheatley, Keith, Khanim, Farhat, Bunce, Chris, Drayson, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463739/
https://www.ncbi.nlm.nih.gov/pubmed/31011660
http://dx.doi.org/10.1016/j.conctc.2019.100361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463739/
https://www.ncbi.nlm.nih.gov/pubmed/31011660
http://dx.doi.org/10.1016/j.conctc.2019.100361

Ejemplares similares